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Abstract. The relative ability of ovine follicle stimulating hormone and its β-subunit, two 
potential candidates for male contraceptive vaccine, to generate antibodies in monkeys  
capable of bioneutralizing follicle stimulating hormone was assessed using in vitro model 
systems. Antiserum against native ovine follicle stimulating hormone was found to be  
highly specific to the intact form with no cross-reactivity with either of the two subunits  
while the antiserum against β-subunit of follicle stimulating hormone could bind to the β- 
subunit in its free form as well as when it is combined with α-subunit to form the intact  
hormone. Both antisera could block the binding of the hormone to the receptor if the  
hormone was preincubated with the antibody. However, the follicle stimulating hormone  
β-antisera could only inhibit the binding of the hormone partially (33% inhibition) if the  
antibody and receptor were mixed prior to the addition of the hormone, while antisera to  
the native follicle stimulating hormone could block the binding completely (100%  
inhibition) in the same experiment. Similarly antisera to the native follicle stimulating  
hormone was significantly effective in blocking (100%) response to follicle stimulating  
hormone but not the β-subunit antisera (0%) as checked using an in vitro granulosa cell  
system. Thus the probability of obtaining antibodies of greater bioneutralization potential  
is much higher if intact hormone is used as an antigen rather than its β-subunit as a  
vaccine. 
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Introduction 
 
 
Immunoneutralization of endogenous follicle stimulating hormone (FSH) (using  
either passive or active immunization approach) has been used in this laboratory in  
the past as a means to gain insight into the mechanism of regulation of ovarian and 
testicular function by FSH both in the rat and in the primate (Moudgal, 1981;  
Sheela Rani and Moudgal, 1983; Moudgal and Dighe, 1985). Based on these studies  
we proposed developing ovine FSH (oFSH) as a contraceptive vaccine for use by  
the human male (Moudgal et al., 1986). Chronic neutralisation of circulating FSH  
in adult male monkeys by specific antibodies has been shown to result in testicular 
dysfunction leading to infertility (Murty et al., 1979). However, it was not clear from 
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these studies how these antibodies act to bring about neutralization of FSH  
bioactivity in vivo—whether by sequestering and reducing peripheral FSH  
concentration and/or also by acting as an effective competitor of the receptor for  
binding FSH. Development of effective FSH vaccine is perhaps dependent upon the 
antigen under test producing antibodies capable of blocking FSH action at both the  
loci described above. The two candidate vaccines considered were intact FSH and  
its β-subunit. Since an antibody capable of blocking hormone-receptor interaction  
in vitro can be assumed to act as a good sequestering agent in vivo also, it was  
considered desirable to develop in vitro model systems wherein the ability of  
antibodies raised to different antigen to block hormone action can be studied. In  
the present study we have compared receptor binding inhibitory activity of an  
antiserum raised against native oFSH to that of an antiserum raised against oFSH  
β-subunit. 
 
 
Materials and methods 
 
 
Antisera 
 
The antisera (a/s) used in these studies were raised in monkeys against highly  
purified oFSH (Sheela Rani and Moudgal, 1977) and its β-subunit (Sairam, 1979;  
Raj et al., 1980). Information on the source and characterization of these a/s is  
provided. 
 
Receptor preparation 
 
The first part of the study was carried out using a particulate receptor preparation  
(PRP) prepared from pig granulosa cells (Sebok et al., 1987). A pool of cells  
obtained during aspiration of pig follicular fluid was collected by centrifugation at  
15,000 g for 30 min at 4°C, washed with 25 mM Tris HCl, pH 7·4, and homogenized  
in the same buffer using an all glass homogenizer. The suspension was finally  
lyophilized and stored at 4°C until used. Lyophilized preparations of the receptor  
have been kept stored for more than 5 years without loss of either [125I]FSH or  
[125I]hCG binding activity. Whenever necessary, suspension of this powder  
(20 mg/ml representing approximately 2 mg protein equivalent/ml) was prepared in  
25 mM Tris-HCl, pH 7·4 containing 10 mM MgCl2 and 0·1% bovine serum  
albumin (designated as RRA buffer). 
Intact granulosa cells isolated from ovarian follicle of 23-day old female rats  
(Charles River, Canada) primed 48 h earlier with 15 IU/rat pregnant mare serum 
gonadotropin (PMSG) were also used as a source of the receptor. Following  
isolation, the cells were washed twice with Dulbecco's modified Eagle's medium and 
resuspended in a large volume of medium to provide approximately 250,000 cells  
per 0·1 ml aliquot. The cells were incubated with [125I ] oFSH in a total volume of  
0·5 ml for different periods at 37°C in a Dubnoff metabolic incubator.
 
General methodology
 
Iodination of oFSH and subunits using carrier free [125I]NaI was carried out
 
FSH and antibody/receptor interaction                                        93
 
according to the procedure of Sairam (1978) and the specific activity of the  
preparation ranged from 50–80 µCi/µg. Each incubation was performed in  
triplicate. The bound hormone was separated by centrifugation and the  
radioactivity in the pellet was determined using an autogamma spectrometer.  
Maximum binding ability of each [125I ] oFSH preparation was determined by  
incubating the tracer with large excess of PRP and was found to vary between  
20–25% of the input. Whenever needed, the antigen-antibody complex was precipi- 
tated using the appropriate second antibody.
Progesterone in the granulosa cell incubation mixture was assayed using a 
radioimmunoassay (RIA) system standardized and routinely used in the laboratory  
(Kato et al., 1983). 
All a/s dilution indicated here are the initial dilutions, 100 µl of each dilution
antiserum being used per tube and the total volume being 500 µl.
 
 
Results 
 
 
Characteristics of the a/s used
 
Of the 3 a/s raised against intact oFSH initially screened for their affinity, specificity  
and capacity, one antiserum was chosen for comparison with antiserum against the  
β-subunit of FSH. Antisera I (raised in a monkey against intact oFSH-NRM 603)  
showed high affinity (as determined by Scatchard analysis of binding data) for  
oFSH (Km– 1·1 × 1010 M − ) with a binding capacity of 130 µg oFSH/ml of serum.
Antisera II (a pool obtained from monkeys immunized against FSH ß-subunit- 
HGM 4) had relatively lower binding affinity for intact oFSH (Km–0·3 × 109 M − ),  
but the binding capacity (165 µg oFSH/ml) of this antiserum was almost similar to  
that shown by a/s I.
The cross reactivity of these two a/s with the subunits of oFSH was determined  
by incubating 0·1 ml of different dilutions of a/s with [125I]labelledá α- and β- 
subunits of oFSH. Both the a/s showed insignificant binding to the α-subunit and  
even this could be observed only at the lowest dilution (1:100 dilution). Binding of 
[125I]FSH β-subunit to a/s II was high, 50% binding being observed at 1:7000  
dilution. Relatively, 50% binding to intact [125I ] FSH was observed at a dilution of 
1:2000. This is to be expected as number of binding sites in the free β-subunit can  
be masked once the β-subunit comes in association with the α to make native FSH. 
Antisera I was found to be more specific for native FSH and could bind labelled  
FSH β-subunit only at very low dilutions (50% binding of [125I] oFSH β being  
observed at a dilution of 1:300). These results showed that a/s I was mostly specific  
for intact oFSH while a/s II could bind to intact oFSH through its β-subunit.
 
Effect of  antibodies on oFSH-receptor interaction using a PRP 
 
Preformed antibody [125I] oFSH complex was unable to bind to FSH receptors  
(table 1). This was demonstrated by preincubating both the a/s (100 µl of 1:2000  
dilution of each a/s) with [125I]oFSH for 2 h at 37°C prior to addition of receptor 
preparation (2 mg PRP/tube) and continuing the incubation for additional 2 h at  
37°C. This experiment essentially showed that either of the a/s at relatively the same
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Table 1. Inability of [125I]oFSH–Ab preformed complex to bind FSH receptors.
 
The complex (hormone-antibody) was formed by incubating [125I]oFSH with 
100 µl of 1:2000 diluted respective antiserum for 60 min at 37°C. At this time 2 mg  
of a lyophylized porcine granulosa cell receptor preparation in 100 µ l of RIA buffer  
was added and incubation continued for 120 min. Amount of [125I] oFSH bound to  
the particulate receptor was determined.
 
 
concentration, despite having different binding affinities were capable of forming a  
firm complex with FSH, preventing its subsequent binding to FSH receptors. 
Ability of the two a/s to compete with the receptor for binding [125I]FSH was 
determined by premixing either of the a/s (100 µl of 1:2000 dilution) with the  
receptor preparation (2 mg PRP/tube) prior to addition of [125I]oFSH. Receptor  
bound radioactivity was determined at the end of 2 h incubation at 37°C. While a/s  
I was able to inhibit 100% the binding [125I] oFSH to its receptor, a/s II was able  
to inhibit, at the same dilution, the binding by only 33% (table 2).
The effect of varying the concentration of the antibody or of the particulate  
receptor preparation on the ability of [125I]oFSH to bind the receptor was next  
determined. Using a constant receptor concentration (2 mg in a total volume of  
500 µl) binding inhibition of 50% could be obtained with 100 µl of 1:5000 diluted  
a/s I (figure 1). Conversely the ability of the receptor protein to effectively compete  
with the antibody for labelled oFSH increased as the receptor concentration was 
enhanced, 8 mg of receptor protein (in a total volume of 500 µl) being required to 
overcome the 50% inhibition of binding obtained when 100 µl of 1:2000 diluted a/s  
I was used. Though the antibody was an effective competitor of the receptor for  
binding labelled oFSH, it was unable to dissociate the [125I]oFSH prebound to the  
PRP even when tested at a high concentration (100 µl of 1:1000). This was  
demonstrated by adding the antiserum after different association times (from  
30–240 min) of the hormone with the PRP (data not shown).
 
 
Table 2. Relative ability of different a/s to prevent [125I] oFSH from binding to the
receptor.
 
*Receptor preparation (2 mg/100 µl) and respective a/s (100 µl of 1:2000 dilution) were 
premixed before addition of [125I]oFSH. Total volume of the reaction mixture was 500 µl  
and incubation time 2 h at 37°C. Results are mean of triplicate determinations. For other 
experimental details see foot note to table 1.
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Figure 1. Effect of varying antibody concentration on the ability of 125I]oFSH to bind  
to receptor. 
[125I]oFSH (approximately 100,000 cpm) was added to tubes containing 2 mg of PRP  
and 100 µl of different dilutions of a/s I and incubated for 2 h at 37°C. At the end of  
incubation the receptor bound radioactivity was determined. The nonspecific binding
determined by incubating [125I] oFSH with PRP in the presence of excess unlabelled
oFSH was subtracted from the total binding observed. The bar indicates specific binding 
observed when [125I] oFSH was incubated with PRP only. The values are mean ± SD of 
triplicate determinations. 
 
 
Interaction of [125I]oFSH with its receptor in intact cells
 
Granulosa cells isolated from ovaries of PM SG primed rats were preincubated with  
[l25I]oFSH for 30, 60 and 120 min at 37°C. After centrifugation and resuspension  
in a fresh medium, the cells were reincubated for 120 min in the presence or absence  
of added a/s. It is evident from figure 2 that a significant portion of the bound  
hormone (59% reduction in binding, Ρ<0·001) was released by a simple expedient  
of incubation of the cells in a hormone free medium. Addition of antiserum I but  
not a/s II to the incubation medium facilitated further discharge of the bound  
hormone (82% reduction in the bound hormone). The experiment also showed that 
association time of the [125I]oFSH with the granulosa cell had apparently no effect  
on the ability of the cell to discharge the bound hormone. It was also observed that 
antibody could dissociate receptor-bound hormone in the intact cells while it was  
unable to do so with particulate receptor (table 3).
 
Ability of FSH a/s to disrupt FSH stimulated steroidogenesis in granulosa cells 
 
Incubation of rat granulosa cells with 50 ng FSH in the presence or absence of 10 µl  
of normal monkey serum resulted in stimulation of production of progesterone.  
Antiserum I was capable of inhibiting FSH response almost totally (98–100%) 
irrespective of whether it was preincubated with FSH or added subsequent to  
mixing cells and FSH in the incubation medium (figure 3). Antiserum II, in  
contrast, was only partially effective in blocking FSH response (48–55% reduction  
in progesterone produced, Ρ < 0·01) and preincubation of FSH with the FSH β- 
antibody did not enhance the inhibition (figure 3).
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Figure 2. Ability of a/s to oFSH and its β-subunit to dissociate [125I] oFSH bound for
different periods to the rat granulosa cells.
Granulosa cells were incubated at 37°C for 30 and 60 min with [125I]oFSH (1st  
incubation). The cells were centrifuged and binding was determined (panel A). The cells  
were resuspended in fresh medium (0·5 ml) containing 10 µl of undiluted a/s I or II and 
reincubated for 120 min at 37°C (2nd incubation). At the end of incubation radioactivity  
bound to the cells was determined. Panels Β and C show the results when the 1st  
incubation was for 30 and 60 min respectively.
 
Table 3. Ability of a/s to discharge [125I] o F S H bound to the
receptor. 
 
The labelled hormone was preincubated with the receptor
Preparation/cells for 1 h at 37°C prior to addition of a/s and
continuing incubation for additional 2h. The receptor/cell
bound radioactivity was determined. The results are mean ±
SD of triplicate determinations. 
* Incubated with 10µl of undiluted a/s.
**Significantly different from controls (P<0·001).
 
 
The necessity of having FSH in the medium throughout the period of incubation  
and ability of the a/s to stop the continued responsiveness of the cell to the bound 
FSH was next tested. The result (figure 4) show that when granulose cells  
preincubted with FSH for 2 h were centrifuged and the medium replaced with 
fresh medium and incubtion continued for additional 2 h, a significant reduction in 
progesterone production over the appropriate controls (52–55% , Ρ <0·01) was
observed. Addition of a/s I to the medium during second incubtion was effective in 
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Figure 3. Ability of FSH a/s added at the beginning of the incubation on response of the  
granulosa cells to FSH. 
Granulosa cells were incubated with either 10 µl NMS or a/s I or II in the presence of  
oFSH (50 ng) for 2 h at 37°C and progesterone secreted into the medium was estimated by  
RIA. 
*FSH in these cases was preincubated with a/s for 30 min prior to addition of cells. 
 
further inhibiting progesterone production (from 52–78%). The a/s II, however, was  
once again ineffective in blocking steroidogenesis stimulated by the bound hormone 
(figure 4). 
 
Discussion 
 
The primary objective of the current study was to understand whether antibodies  
capable of sequestering FSH circulating in vivo are also able to inhibit FSH  
response in vitro and if so the mechanism by which this is achieved. All studies  
carried out hitherto on bioneutralization of endogenous FSH have used either well 
characterized polyclonal antibodies or in active immunization studies, a  
characterized antigen. The chances of obtaining bioneutralization in vivo is perhaps 
greater if more than one hormonal epitope is bound by its specific antibody. These 
determinants need not necessarily be those that interact with the receptor, as steric 
hindrances due to Ag–Ab complex at more than one locus could prevent the  
receptor recognition domain of the hormone from associating with the receptor.
The results of the present study have clearly shown that polyclonal bivalent  
antibodies do make excellent competitors of the receptor for binding to the  
hormone. Of the 4 a/s initially screened two were chosen for detailed study as they 
exhibited specific but different characteristics. It should be noted that both a/s I and  
II have been demonstrated in earlier studies to neutralize the bioactivity of FSH in  
vivo (Murty et al., 1979; Moudgal et al., 1986, 1988; Raj et al., 1980). Antiserum I by 
virtue of its negligible binding to the free α- and β-subunits compared to its binding  
to intact oFSH could be classified as conformation specific. Antiserum II, in 
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Figure 4. Ability of FSH a/s to disrupt ongoing steroidogenesis by granulosa cells under  
FSH stimulation. 
The granulosa cells were preincubated with 50 ng FSH for 2 h. At the end of this  
incubation the cells were centrifuged, supernatant aspirated and the cells resuspended in  
medium (0·5 ml) containing either no addition, or with 10 µl each of NMS or a/s I or II  
and incubated for a further period of 2 h at 37°C. Progesterone secreted into the medium  
was estimated by RIA. Progesterone produced when FSH was incubated with cells for 2 h  
served as controls. The values are mean ± SD of triplicate determinations. (1), Controls  
(cells incubated with FSH for 2 h); (2), medium; (3), NMS; (4), a/s I; (5), a/s II. 
 
 
contrast, by binding to the FSH β-subunit both in its free and combined state  
(intact FSH) showed that it is directed to specific sites in the β-subunit only.  
Though the binding capacity of a/s II was similar to a/s I, its binding affinity was 
relatively lower. While both the a/s used in this study were able to block completely  
the binding of labelled hormone to the particulate receptor preparation if the  
hormone was preincubated with the a/s, underscoring their in vivo sequestering  
property, their behaviour differed if the two binding entities (antibody and receptor)  
were mixed prior to the addition of [125I]oFSH (table 2). It appears from this that  
the inhibition of binding was dependent more on their binding affinity than  
capacity. However, affinity may not be the only factor determining the inhibition  
potency as one of the other a/s raised to intact oFSH having nearly the same  
affinity (~0·5 × 109 M–) as a/s II, proved in competitive experiments to be as good an 
inhibitor of [125I]FSH binding to the receptor as a/s I (data not shown). Poor  
inhibitory capacity can also then be a reflection of epitope specificity. Though the β-
antiserum (a/s II) can be expected to have antibodies to a number of epitopes  
specific to its free state, it is possible that a majority of these epitopes are either  
masked or altered once the β-subunit recombines with the α to form native FSH.  
The epitopes recognized by a/s II in the whole hormone are perhaps those which  
are also directly recognized by the receptor resulting in only partial inhibition of the 
response. In the case of a/s I, however, binding of the antibody to conformationally 
specific site(s) should be preventing the association of the hormone with the  
receptor. It is interesting that the relative inability of the FSH β-a/s (a/s II) to block 
binding or response to FSH observed here is very similar to that exhibited by  
human chorionic gonadotropin (hCG) β-a/s in our earlier studies on hCG-receptor 
interaction (Dighe and Moudgal, 1981, 1983). We had postulated, based on those 
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data, that initial recognition of hCG/luteinizing hormone (LH) by its receptor is  
occurring through sites specifically located in the β-subunit. The current study  
shows that this could be true for FSH also. It appears that for an antibody to be an  
effective inhibitor of hormone response it should bind site(s) involved in either  
direct interaction of the hormone with the receptor or to those located close to such  
sites. All the same in the present study the relative greater efficiency of the  
antiserum to intact FSH in competing with the PRP for binding of labelled  
hormone or blocking response of cells to FSH is perhaps due to antibodies binding  
the hormone at more than one loci/epitope making it difficult, because of steric 
consideration, for the hormone to associate with the receptor.
Another interesting observation that has emerged from the present study is that  
the interaction of FSH with its receptor varies depending upon the type of receptor  
used. While its binding to the particulate receptor preparation is tight even at early 
association times, its binding to cell-associated receptor is loose and a significant  
amount of the bound hormone dissociates upon incubating the cells in a hormone  
free medium. Unlike in the case of hCG where exposure of cells to the hormone for  
as short as 15 min is adequate to provide a full 2 h response (Dighe and Moudgal,  
1983), continued association of FSH with the cellular receptor is essential for it to 
produce a sustained response. In this respect, oFSH appears to resemble PMSG  
and rat LH (Sheela Rani and Moudgal, 1985).
In conclusion, it can be stated that all polyclonal a/s capable of binding the  
hormone per se (radiolabelled or otherwise) need not necessarily be good  
competitors of hormone binding to the receptor. For complete bioneutralization in 
 vivo, however, the antibodies in addition to being able to sequester the circulating 
hormone with high affinity should perhaps be also effective competitors of hormone 
binding to the receptor. Using the above criteria we believe intact oFSH rather  
than its β-subunit could turn out to be a better contraceptive vaccine. Studies  
carried out so far have shown that active immunization with intact oFSH results in 
antibodies which block binding of FSH to its receptors. These antibodies in turn  
cause infertility in the primate without having any effect on LH dependent functions 
underscoring the specificity of the vaccine (Moudgal et al., 1986, 1988).
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